Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Medical Treatments

Department of Health written question – answered on 17th June 2016.

Alert me about debates like this

Photo of Andrew Gwynne Andrew Gwynne Shadow Minister (Health)

To ask the Secretary of State for Health, what steps he is taking to encourage NHS England and the Medicines and Healthcare Products Regulatory Agency to collaborate to ensure aseptic capacity is managed to a commonly high standard, is reimbursed at a sustainable level and supports further investment to meet growing demand in the NHS.

Photo of Andrew Gwynne Andrew Gwynne Shadow Minister (Health)

To ask the Secretary of State for Health, what assessment NHS England has made of variation in aseptic services and the delivery of high quality infusional chemotherapy to cancer patients.

Photo of Andrew Gwynne Andrew Gwynne Shadow Minister (Health)

To ask the Secretary of State for Health, what assessment NHS England has made of the capacity in the NHS to meet the demand for aseptic services.

Photo of Jane Ellison Jane Ellison The Parliamentary Under-Secretary of State for Health

NHS England Specialist Pharmacy Services have to date not undertaken a comprehensive assessment of aseptic capacity to meet the future demands for chemotherapy provision in England. They are currently working closely with colleagues at the Department and NHS Improvement to support a number of regionally based reviews of aseptic capacity and to help trusts develop local and regional Hospital Pharmacy Transformation plans, as recommended by Lord Carter in February 2016.

The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department and is responsible for regulating unlicensed medicines under a Manufacturer's 'Specials' Licence. The General Pharmaceutical Council (GPhC) and Care Quality Commission (CQC) are responsible for regulating medicine prepared extemporaneously in a register pharmacy or hospital pharmacy respectively under the professional exemption.

MHRA will collaborate with the NHS, GPhC and CQC though inspections of MHRA licensed aseptic facilities or joint investigations of aseptic facilities in hospitals where there are patient safety concerns.

Does this answer the above question?

Yes1 person thinks so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.